A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
← catalyst calendarNCT06921837 · readout ≤ 285 d
Sponsored by Bolt Biotherapeutics, Inc. (industry) · BOLT — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
122estimated
Sites
16
Countries
Australia, South Korea, Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-26 | actual | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Cancer Adenocarcinoma Metastatic
- Gastroesophageal Adenocarcinoma
Intervention
- Drug: BDC-4182
Primary outcomes
what the primary-completion date above is the date OFIncidence of adverse events (AEs) and serious adverse events (SAEs) graded according to CTCAE v5.0
measured approximately 2 years
Incidence and nature of AEs considered by the Investigator or Sponsor to be clinically relevant, attributable to study treatment, and meeting dose-limiting toxicity (DLT) criteria
measured Up to 21 days
Permalink · BOLT's whole pipeline · Catalyst calendar · Every registered study · What changed